Stock Market News
Midatech narrows losses ahead of 2018 'inflection points'
(WebFG News) - Pharmaceutical company Midatech Pharma narrowed losses in its most recent trading year as gross revenues expanded just short of one-third on an improved US sales performance.
Midatech's total gross revenues for the calendar year grew 31% to £12.08m, the majority of which was a result of product sales generated by its US commercial business of £11.13m - itself a 49% year-on-year increase.
However, the Oxford-based group, which had three separate drugs still in the research and development phase throughout the year, booked a net loss after tax of £16.06m, a 20.34% improvement on 2016's figures, as the cost of that same R&D ballooned from £7.8m to £10.19m. On the bright side, the US business was breakeven at the EBITDA level in the second half of the year.
Midatech saw positive clinical trial readouts for Q-Octreotide, for carcinoid cancer, with a pivotal trial this MTD201 programme expected to begin in April, and also made regulatory submissions to the US Food & Drug Administration on the MTX110 stem cell programme for paediatric brain cancer cancer, where a potentially pivotal Phase I/II trial should begin before long.
Elsewhere, the AIM-listed company embarked on a study of Gelclair, a product already available for a complication of cancer called oral mucositis.
In order to fund its extensive drug pipeline, Midatech entered into a senior secured $15m loan agreement with MidCap Financial Trust in the fourth quarter of 2017, $7m of which has been received with the remaining $8m dependent on clinical development milestones. There was £13.2m of net cash at the period end.
Midatech's chief executive officer, Dr Craig Cook, said, "2017 was a year of significant change and progress for Midatech. We have continued the development of our three lead oncology drug candidates and we now have exciting value inflection points coming up in 2018. Additionally, we made good progress with our immunotherapy assets, which are now advancing toward potential clinical development. Our US commercial business recorded solid growth, achieving a breakeven EBITDA in the second half of the year."
"With additional funding secured, we are well-resourced to drive towards our clinical objectives. We are enthused by the prospect of delivering transformative therapies to improve patients' lives and progressing our R&D pipeline forward to address unmet needs in significant markets, driving future profitability and creating value for stakeholders," Cook added.
As of 1340 BST, shares had declined 11.11% to 24.00p.
Midatech's total gross revenues for the calendar year grew 31% to £12.08m, the majority of which was a result of product sales generated by its US commercial business of £11.13m - itself a 49% year-on-year increase.
However, the Oxford-based group, which had three separate drugs still in the research and development phase throughout the year, booked a net loss after tax of £16.06m, a 20.34% improvement on 2016's figures, as the cost of that same R&D ballooned from £7.8m to £10.19m. On the bright side, the US business was breakeven at the EBITDA level in the second half of the year.
Midatech saw positive clinical trial readouts for Q-Octreotide, for carcinoid cancer, with a pivotal trial this MTD201 programme expected to begin in April, and also made regulatory submissions to the US Food & Drug Administration on the MTX110 stem cell programme for paediatric brain cancer cancer, where a potentially pivotal Phase I/II trial should begin before long.
Elsewhere, the AIM-listed company embarked on a study of Gelclair, a product already available for a complication of cancer called oral mucositis.
In order to fund its extensive drug pipeline, Midatech entered into a senior secured $15m loan agreement with MidCap Financial Trust in the fourth quarter of 2017, $7m of which has been received with the remaining $8m dependent on clinical development milestones. There was £13.2m of net cash at the period end.
Midatech's chief executive officer, Dr Craig Cook, said, "2017 was a year of significant change and progress for Midatech. We have continued the development of our three lead oncology drug candidates and we now have exciting value inflection points coming up in 2018. Additionally, we made good progress with our immunotherapy assets, which are now advancing toward potential clinical development. Our US commercial business recorded solid growth, achieving a breakeven EBITDA in the second half of the year."
"With additional funding secured, we are well-resourced to drive towards our clinical objectives. We are enthused by the prospect of delivering transformative therapies to improve patients' lives and progressing our R&D pipeline forward to address unmet needs in significant markets, driving future profitability and creating value for stakeholders," Cook added.
As of 1340 BST, shares had declined 11.11% to 24.00p.
Related share prices |
---|
Midatech Pharma (MTPH) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price